Nektar Therapeutics (NKTR) Shares Up 0%
Shares of Nektar Therapeutics (NASDAQ:NKTR) shot up 0% during mid-day trading on Monday . The stock traded as high as $79.39 and last traded at $78.70. 2,270,000 shares changed hands during trading, a decline of 16% from the average session volume of 2,710,000 shares. The stock had previously closed at $78.70.
Several brokerages have recently issued reports on NKTR. BidaskClub cut shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Canaccord Genuity restated a “buy” rating and set a $80.00 target price (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Roth Capital set a $45.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 target price on shares of Nektar Therapeutics in a research report on Monday, November 13th. Finally, Mizuho upped their target price on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 14th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $46.17.
The stock has a market cap of $12,390.00, a price-to-earnings ratio of -110.85 and a beta of 2.04. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.
A number of hedge funds have recently modified their holdings of the business. Carillon Tower Advisers Inc. bought a new position in Nektar Therapeutics in the 4th quarter worth about $43,024,000. Alexandria Capital LLC bought a new position in Nektar Therapeutics in the 4th quarter worth about $5,942,000. Opaleye Management Inc. bought a new position in Nektar Therapeutics in the 4th quarter worth about $4,777,000. Virtus Fund Advisers LLC bought a new position in Nektar Therapeutics in the 4th quarter worth about $1,009,000. Finally, BlackRock Inc. grew its stake in Nektar Therapeutics by 2.1% in the 4th quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock worth $1,279,883,000 after acquiring an additional 431,269 shares in the last quarter. Institutional investors and hedge funds own 96.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Nektar Therapeutics (NKTR) Shares Up 0%” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/nektar-therapeutics-nktr-shares-up-0/1862000.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.